Evidence map›Paper›PMID 27349335›Full record

ArticleAIDS research and human retroviruses

Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection.

Raabya Rossenkhan, Iain J MacLeod, Zabrina L Brumme, Craig A Magaret, Theresa K Sebunya, Rosemary Musonda, Berhanu A Gashe, Paul T Edlefsen, Vlad Novitsky, M Essex

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Raabya Rossenkhan1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts.
Iain J MacLeod1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts.
Zabrina L Brumme5 Faculty of Health Sciences, Simon Fraser University , Burnaby, Canada .
Craig A Magaret4 Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center , Seattle, Washington.
Theresa K Sebunya3 Department of Biological Sciences, University of Botswana , Gaborone, Botswana .
Rosemary Musonda1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts.
Berhanu A Gashe3 Department of Biological Sciences, University of Botswana , Gaborone, Botswana .
Paul T Edlefsen4 Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center , Seattle, Washington.
Vlad Novitsky1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts.
M Essex1 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachusetts.
Botswana Harvard AIDS Institute Partnership · BWFred Hutch Cancer Center · USUniversity of Botswana · BWSimon Fraser University · CA

Funding

SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Markers of Viral Set Point in Primary HIV-1C InfectionR01AI057027 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI NOVITSKY, VLADIMIR A · 2005 to 2009
$2.2M
CIHRFIC NIH HHS D43 TW000004FIC NIH HHS D43 TW009610NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI057027NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Viral variants that predominate during early infection may exhibit constrained diversity compared with those found during chronic infection and could contain amino acid signature patterns that may enhance transmission, establish productive infection, and influence early events that modulate the infection course. We compared amino acid distributions in 17 patients recently infected with HIV-1C with patients with chronic infection. We found significantly lower entropy in inferred transmitted/founder (t/f) compared with chronic viruses and identified signature patterns in Vif and Vpr from inferred t/f viruses. We investigated sequence evolution longitudinally up to 500 days postseroconversion and compared the impact of selected substitutions on predicted human leukocyte antigen (HLA) binding affinities of published and predicted cytotoxic T-lymphocyte epitopes. Polymorphisms in Vif and Vpr during early infection occurred more frequently at epitope-HLA anchor residues and significantly decreased predicted epitope-HLA binding. Transmission-associated sequence signatures may have implications for novel strategies to prevent HIV-1 transmission.

Indexed as

Selection, GeneticAdultAmino Acid SequenceEpitopesEvolution, MolecularFemaleGenotypeHIV-1HIV InfectionsHuman Immunodeficiency Virus ProteinsHumansLongitudinal StudiesMalevif Gene Products, Human Immunodeficiency VirusViral Regulatory and Accessory ProteinsViroporin ProteinsEpitopesHuman Immunodeficiency Virus Proteinsvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1Viral Regulatory and Accessory ProteinsViroporin Proteinsvpr Gene Products, Human Immunodeficiency Virusvpr protein, Human immunodeficiency virus 1vpu protein, Human immunodeficiency virus 1accessory genesCTL epitopeevolutionHIV transmissionVifVprVpu

Identifiers

PMID27349335
PMCPMC5067802
OpenAlexW2467570932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.